Vertex Reports Third Quarter 2024 Financial Results

Sep 30, 2024 · The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.

CouponFollow Extension

12%
OFF

Vertex Pharmaceuticals Reports Strong Q3 2024 Growth - Nasdaq

3 weeks from now

Nov 5, 2024 · Vertex Pharmaceuticals has reported a significant financial performance in the third quarter of 2024, with a product revenue of $2.77 billion, marking a 12% increase compared to …

nasdaq.com

12%
OFF

Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript

3 weeks from now

Nov 4, 2024 · Vertex’s impressive Q3 results reaffirm our strong performance and growth trajectory. In Q3 2024, the company reported a revenue increase of 12% year-over-year, …

wallstreetwaves.com

93%
OFF

Vertex Pharmaceuticals Tops Q3 Estimates - The Motley Fool

3 weeks from now

Nov 4, 2024 · Vertex Pharmaceuticals (VRTX 0.93%), a leader in cystic fibrosis treatments, released its third-quarter results on Nov. 4. The report highlighted significant growth, with …

fool.com

$4.38
OFF

Vertex Pharmaceuticals Reports Q3 Adjusted EPS $4.38, Consensus …

3 weeks from now

Nov 4, 2024 · Reports Q3 revenue $2.77B, consensus $2.72B. “The third quarter marked another period of strong progress, with continued revenue growth and outstanding execution across …

businessinsider.com

$4.38
OFF

Vertex Pharmaceuticals (VRTX) Earnings Date And Reports 2025

3 weeks from now

Vertex Pharmaceuticals posted Q3 2024 earnings on November 4, 2024, reporting an EPS of $4.38, which topped analysts' consensus estimates of $3.61 by $0.77. Quarterly revenue rose …

marketbeat.com

6%
OFF

Vertex Pharmaceuticals Reports Strong Q3 Earnings, Surpassing ...

3 weeks from now

Nov 6, 2024 · Vertex Pharmaceuticals has demonstrated impressive financial resilience with a Q3 profit of $1.045 billion and an 11.6% revenue increase, even amidst market fluctuations. Can …

folikoinsights.com

6%
OFF

Vertex Pharmaceuticals Reports Strong Q3 Revenue Growth Amid …

3 weeks from now

Jan 18, 2025 · Vertex Pharmaceuticals showcases resilience with an impressive 11.6% revenue growth in Q3 2024, despite facing stock challenges. As the FDA decision on suzetrigine …

folikoinsights.com

$11
OFF

Is Vertex Pharmaceuticals Stock A Buy In 2025? - The Motley Fool

3 weeks from now

Jan 26, 2025 · Vertex stock trades at 23.8 times forward earnings (in line with the S&P 500), with $11.2 billion in cash and strong growth prospects.

fool.com

12%
OFF

Vertex Reports Third Quarter 2024 Financial Results

3 weeks from now

Nov 4, 2024 · Vertex Pharmaceuticals reported strong Q3 2024 results with product revenue of $2.77 billion, up 12% year-over-year. The company raised its full-year 2024 product revenue …

stocktitan.net

8%
OFF

[Ad Hoc Announcement Pursuant To Art. 53 LR] Roche Reports …

3 weeks from now

4 days ago · Sales in the Pharmaceuticals Division increased by 8% to CHF 46.2 billion, with newer medicines for severe diseases continuing their strong growth. The top four growth …

roche.com

12%
OFF

Vertex Reports Third Quarter 2024 Financial Results - Morningstar

3 weeks from now

Nov 4, 2024 · Vertex Reports Third Quarter 2024 Financial Results — Product revenue of $2.77 billion, a 12% increase compared to Q3 2023 — — Raising full-year product revenue guidance …

morningstar.com

$545
OFF

BMO Raises Vertex Stock Price Target To $545 From $520

3 weeks from now

3 days ago · On Friday, BMO Capital Markets increased its price target on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares, moving the goalpost from $520 to …

investing.com

FAQs about Vertex Reports Third Quarter 2024 Financial Results Coupon?

How did Vertex Pharmaceuticals (VRTX) perform in Q3 2024?

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported a 12% year-over-year revenue growth for Q3 2024, reaching $2.77 billion. The company increased its full-year product revenue guidance to $10.8 billion to $10.9 billion, reflecting strong growth and performance. ...

How much did Vertex Pharmaceuticals earn in a quarter?

Vertex Pharmaceuticals last announced its quarterly earnings results on May 6th, 2024. The pharmaceutical company reported $4.76 earnings per share for the quarter, topping the consensus estimate of $3.66 by $1.10. The firm earned $2.69 billion during the quarter, compared to analysts' expectations of $2.58 billion. ...

When is Vertex Pharmaceuticals' next earnings release date?

Vertex Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based off last year's report dates. Learn more on VRTX's earnings history. Did Vertex Pharmaceuticals beat their earnings estimates last quarter? ...

Is vertex a good stock to buy in 2024?

Vertex appears quite expensive at 900x earnings estimates for 2024, which will become trailing earnings once the company releases its Q4 results on February 10. However, 2024 earnings are greatly impacted by the expense of multiple Phase 3 clinical trials, in addition to the acquisition of Alpine Immune Sciences for $4.9 billion in cash last year. ...

Is Vertex Pharmaceuticals a good stock to buy in 2025?

Vertex Pharmaceuticals continues to execute its commercialization of three new drugs, JOURNAVX, CASGEVY, and ALYFTREK. Two of which have been approved by the FDA since December. Vertex's valuation appears high due to recent expenses, but analysts expect substantial earnings growth in 2025 as acquisition and clinical expenses subside. ...

What is vertex's financial guidance for 2024?

Vertex today reiterated its full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion. Vertex’s product revenue guidance includes expectations for continued growth in CF as well as for the launch of CASGEVY in approved indications and geographies. ...